MENLO PARK, Calif. , Sept. 3, 2025 /PRNewswire/ -- MyOme, a leading clinical whole genome testing and polygenic risk modelling (PRS) company, today announced the launch of its Type 2 Diabetes (T2D) Integrated Polygenic Risk Score™ (iPRS). The new report, available as part of MyOme's Proactive Health products, empowers individuals and their healthcare providers with a more comprehensive understanding of inherited risk for developing T2D, one of the most prevalent chronic diseases worldwide.

According to the Centers for Disease Control and Prevention (CDC), more than 1 in 10 Americans—over 37 million people—have diabetes, with T2D accounting for 90–95% of cases.¹ An additional 96 million U.S. adults—over 1 in 3—have prediabetes, placing them at increased risk for developing T2D.² Diab

See Full Page